BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. announced today that Vicente Anido, Jr.,
Ph.D., was named Chairman of Aerie’s Board of Directors. Dr. Anido is a
well-respected ophthalmology industry veteran and leader, who most
recently served as President and Chief Executive Officer of ISTA
Pharmaceuticals prior to its acquisition by Bausch + Lomb. Aerie also
announced that David Epstein, M.D., Chairman, Department of
Ophthalmology, Duke University School of Medicine, and Aerie Co-Founder,
has been named as Chairman of the Company’s Scientific Advisory Board.
“David has served as a long-time Aerie Board
member and has been a highly valued member of the team since he
participated in the Company’s founding in 2005. We are very pleased to
have him take this important leadership position heading our Scientific
Advisory Board.”
“On behalf of the Aerie Board and Aerie’s employees, we welcome Vince
Anido as our new Chairman, and we look forward to his contributions to
Aerie’s continuing success in advancing our novel glaucoma product
candidates,” said Thomas van Haarlem, M.D., Aerie’s President and Chief
Executive Officer.
From 2001 to 2012, Dr. Anido was President, Chief Executive Officer and
a Director of ISTA Pharmaceuticals. Prior to this, Dr. Anido was general
partner of Windamere Venture partners, served as President and CEO of
CombiChem, Inc., a biotechnology company, and was President of the
Americas Region of Allergan, a specialty pharmaceutical company focusing
on ophthalmology, dermatology and neuromuscular indications. Dr. Anido
currently serves on the Board of Directors of QLT, Inc. and Depomed,
Inc., both of which are NASDAQ-listed pharmaceutical companies. He
received a B.S. in Pharmacy and an M.S. in Pharmacy Administration from
West Virginia University, and a Ph.D. in Pharmacy Administration from
the University of Missouri-Kansas City.
Dr. Epstein has spent many years addressing the core problem in glaucoma
– abnormalities of the trabecular meshwork. He has been honored by a
long list of awards throughout his career, and has held several
leadership positions in ophthalmology associations, including President
of the Association of University Professors of Ophthalmology (AUPO) from
2011 to 2012, President of the Chandler-Grant Glaucoma Society (2004 -
2005), and President of the Association for Research in Vision and
Ophthalmology (ARVO) (1992 – 1993), which will be recognizing Dr.
Epstein with the Mildred Weisenfeld Award for Excellence in
Ophthalmology, to be presented at the 2013 ARVO Annual Meeting in May.
Dr. van Haarlem stated, “David has served as a long-time Aerie Board
member and has been a highly valued member of the team since he
participated in the Company’s founding in 2005. We are very pleased to
have him take this important leadership position heading our Scientific
Advisory Board.”
About Aerie Pharmaceuticals
Aerie Pharmaceuticals is a privately held pharmaceutical company in late
Phase 2 dedicated to the discovery and development of novel
small-molecule treatments for glaucoma. Aerie’s internal research and
development engine has generated an innovative glaucoma pipeline of
three proprietary products, all of which are well tolerated, high
efficacy, once-daily eye drop therapies that include the first new
mechanisms of action for glaucoma treatment in nearly 20 years.
The Company’s lead product candidate, AR-12286, is a highly selective
Rho Kinase inhibitor that is the first glaucoma therapy to reduce
intraocular pressure by relaxing and clearing the trabecular meshwork,
which is the eye’s main fluid drain. AR-12286 is expected to be the new,
convenient second-line glaucoma drug of choice, in a market where nearly
half of patients require second-line or add-on therapy. Aerie’s PG286
fixed combination with travoprost is the first glaucoma therapy to lower
intraocular pressure by opening both of the eye’s fluid drains. This new
second-line therapy offers the convenience of two drugs in one eye drop
and the highest efficacy of any single drop glaucoma medication. The
Company’s third product, AR-13324, is a potential first line therapy and
the first of a new dual action drug class that reduces the eye’s fluid
inflow while also increasing fluid outflow through the trabecular
meshwork drain, all in a highly effective single drop per day.
Aerie is located in Bedminster, New Jersey and Research Triangle Park,
North Carolina. Further information on the Company is available at www.aeriepharma.com.
Email 
Special home delivery offers!
